Related Experiment Video
Updated: Mar 30, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.4K
Correlation of GLUT9 Polymorphisms With Gout Risk
Qingxi Meng1, Ji Yue, Mingfu Shang
1From the Department of Spinal Cord Injury, Institute of Orthopedics and Traumatology of Chinese PLA, General Hospital of Jinan Military Area Command, Jinan, Shandong, China.
Medicine
|November 12, 2015
Summary
Genetic variations in glucose transporter 9 (GLUT9) single nucleotide polymorphisms (SNPs) are linked to gout risk. Specifically, rs16890979 and rs7442295 GLUT9 polymorphisms appear to decrease the likelihood of developing gout.
Area of Science:
- Genetics
- Metabolic Disorders
- Pharmacogenomics
Background:
- Single nucleotide polymorphisms (SNPs) at the glucose transporter 9 (GLUT9) locus are associated with uric acid levels, a primary risk factor for gout.
- Understanding the role of specific GLUT9 polymorphisms in gout pathogenesis is crucial for targeted interventions.
Purpose of the Study:
- To investigate the association between common GLUT9 polymorphisms (rs16890979, rs6855911, and rs7442295) and the risk of developing gout.
- To test the hypothesis that these GLUT9 variants influence gout susceptibility.
Main Methods:
- A meta-analysis approach was employed, synthesizing data from multiple studies.
- Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using fixed- or random-effect models.
- Subgroup analyses were conducted based on ethnicity and gender for the investigated SNPs.
Main Results:
- Meta-analyses indicated a significantly reduced risk of gout associated with the rs16890979 polymorphism under dominant, heterozygote, and allele frequency models.
- This decreased risk for rs16890979 was particularly noted in Asian populations.
- The rs7442295 polymorphism also showed a decreased gout risk in total samples and in males.
- No significant association was found between the rs6855911 polymorphism and gout risk.
Conclusions:
- The findings support the hypothesis that GLUT9 polymorphisms, specifically rs16890979 and rs7442295, are associated with gout risk.
- These genetic variants may play a role in the susceptibility to gout, offering potential targets for future research and therapeutic strategies.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
109
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
123
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
123
01:11Genome-wide Association Studies-GWAS
16.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.6K
01:05Single Nucleotide Polymorphisms-SNPs
19.8K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.8K
01:29Pharmacogenomics: Identification of New Drug Targets
77
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
77
01:27Principles of Pharmacogenetics: Types of Genetic Variants
95
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
95